Our results may identify NaV1.8 as a potential novel therapeutic target for antiarrhythmic intervention aiming at modulating the neural control of the ischemic heart to treat patients with refractory ventricular arrhythmias or electrical storm. The gene discussed is SCN10A; the disease is Ventricular arrhythmia.